TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39282905

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy plus perioperative chemotherapy
Number of subjects: 574

Group type: COMPARATOR
Intervention: Perioperative chemotherapy alone (control)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy
Number of subjects: 574

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (control)
Number of subjects: 574
Study: 39282913

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 298
Study: 39282906

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy group
Number of subjects: 1174

Group type: COMPARATOR
Intervention: Placebo-chemotherapy group
Number of subjects: 1174
Study: 39282910

Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin every 3 weeks for four cycles, followed by radical cystectomy and adjuvant durvalumab every 4 weeks for eight cycles.
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Neoadjuvant gemcitabine-cisplatin followed by radical cystectomy alone.
Number of subjects: 1063

Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin.
Number of subjects: 1063
Study: 39283020

Group type: EXPERIMENTAL
Intervention: Sense of coherence scale
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Intercultural sensitivity scale
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Work-related strain inventory
Number of subjects: 136
Study: 39283176

Group type: EXPERIMENTAL
Intervention: Take a STAND for Health (TS4H)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 103
Study: 39283178

Group type: EXPERIMENTAL
Intervention: Virtual visitation
Number of subjects: 38
Study: 39283227

Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EX
Number of subjects: 60
Study: 39283231

Group type: EXPERIMENTAL
Intervention: Fasted exercise training (exercise after an overnight fast)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postprandial exercise training (exercise after morning meal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fasted exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postprandial exercise training
Number of subjects: 20
Study: 39283234

Group type: EXPERIMENTAL
Intervention: Individualized, goal-oriented intervention; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 39283252

Group type: EXPERIMENTAL
Intervention: Family functioning (support and bonding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss program (WW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-guided group
Number of subjects: 0
Study: 39283290

Group type: EXPERIMENTAL
Intervention: Itacitinib 400 mg orally daily, 28-day cycle
Number of subjects: 25
Study: 39283299

Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capivasertib plus fulvestrant (in participants with detectable PIK3CA, AKT1, and/or PTEN alterations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (in participants with detectable PIK3CA, AKT1, and/or PTEN alterations)
Number of subjects: 0
Study: 39283417

Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg once daily
Number of subjects: 0
Study: 39283627

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Erenumab (combined groups)
Number of subjects: 620
Study: 39283633

Group type: EXPERIMENTAL
Intervention: 3D digital model intervention group
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (usual preoperative planning)
Number of subjects: 92
Study: 39283649

Group type: EXPERIMENTAL
Intervention: High-intensity NPPV (n=147)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Low-intensity NPPV (n=153)
Number of subjects: 300
Study: 39283667

Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes plus counseling
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Nonnicotine e-cigarettes plus counseling
Number of subjects: 257

Group type: COMPARATOR
Intervention: Counseling alone
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Smoking abstinent participants
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Overall comparison across groups
Number of subjects: 257
Study: 39283873

Group type: EXPERIMENTAL
Intervention: Monitoring ORI values with a target of at least 0.6 for at least 1 minute during preoxygenation.
Number of subjects: 950

Group type: COMPARATOR
Intervention: Standard pulse oximeter monitoring of SpO2 values during preoxygenation, aiming for 100% SpO2 for at least 3 minutes.
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 950
Study: 39283901

Group type: EXPERIMENTAL
Intervention: OASIS Walking Intervention (up to 45 minutes per session, 5 sessions per week, for 6 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Client Satisfaction Questionnaire
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Feasibility measures
Number of subjects: 26
Study: 39284021

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation (CI) after tumor removal
Number of subjects: 37
Study: 39284030

Group type: EXPERIMENTAL
Intervention: Gene therapy using adeno-associated virus to deliver interleukin-1 receptor antagonist (IL-1Ra) via direct in vivo injection into the joint.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy using adeno-associated virus to deliver IL-1Ra.
Number of subjects: 0
Study: 39284103

Group type: EXPERIMENTAL
Intervention: NeuroCARE (psychological intervention consisting of six telehealth sessions with a behavioral health specialist)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NeuroCARE
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 39284179

Group type: EXPERIMENTAL
Intervention: TAU+Fam-AID
Number of subjects: 60

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 60
Study: 39284329

Group type: EXPERIMENTAL
Intervention: Tivozanib plus nivolumab (0.89 mg per day orally + 480 mg every 4 weeks intravenously)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Tivozanib monotherapy (1.34 mg per day orally)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Tivozanib plus nivolumab (for patients with ICI as immediate previous therapy)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Tivozanib monotherapy (for patients with ICI as immediate previous therapy)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Tivozanib plus nivolumab (for patients with non-ICI as immediate previous therapy)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Tivozanib monotherapy (for patients with non-ICI as immediate previous therapy)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Tivozanib plus nivolumab
Number of subjects: 343

Group type: COMPARATOR
Intervention: Tivozanib monotherapy
Number of subjects: 343
Study: 39284337

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily until unacceptable toxicity, disease progression, or patient decision to withdraw.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg once daily
Number of subjects: 61
Study: 39284383

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in dMMR population
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo in pMMR population
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1095
Study: 39284439

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: ICARUS score
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Age ≥ 75 years
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Acute coronary syndrome at presentation
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 1071
Study: 39284453

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Green-Mediterranean diet (green-MED)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Healthy dietary guidelines
Number of subjects: 284
Study: 39284482

Group type: EXPERIMENTAL
Intervention: Abnormal ECG tracing
Number of subjects: 5876

Group type: COMPARATOR
Intervention: Normal ECG tracing
Number of subjects: 5876

Group type: EXPERIMENTAL
Intervention: ST-segment depression
Number of subjects: 5876

Group type: EXPERIMENTAL
Intervention: T-wave inversion
Number of subjects: 5876

Group type: EXPERIMENTAL
Intervention: LBBB
Number of subjects: 5876

Group type: EXPERIMENTAL
Intervention: RBBB
Number of subjects: 5876
Study: 39284531

Group type: EXPERIMENTAL
Intervention: Pomegranate extract supplementation for 2 cycles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 39284678

Group type: EXPERIMENTAL
Intervention: Zeiss Callisto system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Alcon system
Number of subjects: 15
Study: 39284697

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily (after 1 month at 40 mg daily)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 1050
Study: 39284953

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nivolumab alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (chemotherapy)
Number of subjects: 0
Study: 39285121

Group type: EXPERIMENTAL
Intervention: PASI 100
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: PASI 95%
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: PASI 90%
Number of subjects: 743
Study: 39285295

Group type: EXPERIMENTAL
Intervention: LDL-C levels > 2.6 mmol/L (Groups 3 and 4)
Number of subjects: 243

Group type: COMPARATOR
Intervention: LDL-C levels ≤ 2.6 mmol/L (Groups 1 and 2)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: LDL-C levels correlation
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: FAZ area, macular thickness, RNFL thickness
Number of subjects: 243
Study: 39285305

Group type: EXPERIMENTAL
Intervention: Audit and feedback (A&F) letters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications to the A&F interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A&F on antibiotic prescription duration
Number of subjects: 0
Study: 39285308

Group type: EXPERIMENTAL
Intervention: Arm 1: Intervention operations guide, on-site clinical champion, peer community of practice, patient engagement tools.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arm 2: All strategies from Arm 1 plus assistance from an external facilitator.
Number of subjects: 8
Study: 39285313

Group type: EXPERIMENTAL
Intervention: Intrauterine estrogen-releasing system
Number of subjects: 250

Group type: COMPARATOR
Intervention: Foley catheter balloon combined with oral estrogen therapy
Number of subjects: 250
Study: 39285365

Group type: EXPERIMENTAL
Intervention: Psychoeducational programme supplementing Treatment As Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 0
Study: 39285405

Group type: EXPERIMENTAL
Intervention: Caring for Providers to Improve Patient Experience (CPIPE) intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2000
Study: 39285418

Group type: EXPERIMENTAL
Intervention: Investigational gene therapy (resamirigene bilparvovec)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 39285437

Group type: EXPERIMENTAL
Intervention: Ketoprofen (NSAID) 100 mg every 12 hours for 48 hours after surgery
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo (NSAID) every 12 hours for 48 hours after surgery
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Ketoprofen (NSAID)
Number of subjects: 238
Study: 39286230

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 39286233

Group type: EXPERIMENTAL
Intervention: Heated eye mask (HEM) followed by eyelid massage device EyePeace (EP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study: 39286281

Group type: EXPERIMENTAL
Intervention: Mental Health Support Interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 39286494

Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 0

Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 0
Study: 39286575

Group type: EXPERIMENTAL
Intervention: 30 μg sprifermin every 12 months
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 30 μg sprifermin every 6 months
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 100 μg sprifermin every 12 months
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 100 μg sprifermin every 6 months
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 39286636

Group type: EXPERIMENTAL
Intervention: LY01610 at 60 mg/m²
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LY01610 at 80 mg/m²
Number of subjects: 66
Study: 39286890

Group type: EXPERIMENTAL
Intervention: Pulmonary Endarterectomy (PEA)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty (BPA)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Medical Therapy (Pulmonary Hypertension Drugs)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: No PEA/BPA
Number of subjects: 1009
Study: 39286899

Group type: EXPERIMENTAL
Intervention: CCTA-guided Invasive Coronary Angiography (CCTA-ICA)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Classic Invasive Coronary Angiography (ICA-only)
Number of subjects: 225
Study: 39286935

Group type: EXPERIMENTAL
Intervention: Raltitrexed + Irinotecan (SALIRI) plus bevacizumab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Raltitrexed + Oxaliplatin (SALOX) plus bevacizumab
Number of subjects: 100
Study: 39286985

Group type: EXPERIMENTAL
Intervention: Prebiotic blend consisting of inulin and oligofructose
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 39287102

Group type: EXPERIMENTAL
Intervention: Preoperative assessment of U neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acid-binding protein (L-FABP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined assessment of U osmolality (OSM), U kidney injury molecule 1 (KIM-1), and tissue inhibitor of metalloproteinase (TIMP-1) within 48 h post-LT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: U osmolality (OSM) alone, measured within 48 h post-LT
Number of subjects: 100
Study: 39287124

Group type: EXPERIMENTAL
Intervention: Pimicotinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (surgery)
Number of subjects: 0
Study: 39287147

Group type: EXPERIMENTAL
Intervention: D-VRd (daratumumab, bortezomib, lenalidomide, dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VRd (bortezomib, lenalidomide, dexamethasone)
Number of subjects: 0
Study: 39287158

Group type: EXPERIMENTAL
Intervention: Benralizumab (Fasenra)
Number of subjects: 0
Study: 39287249

Group type: EXPERIMENTAL
Intervention: sugammadex 2 mg/kg (Group S)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sugammadex 1 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S1N)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sugammadex 1.5 mg/kg with neostigmine 20 µg/kg + atropine 10 µg/kg (Group S2N)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sugammadex (both doses) with neostigmine
Number of subjects: 90
Study: 39287491

Group type: EXPERIMENTAL
Intervention: Proton therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon therapy
Number of subjects: 0
Study: 39287519

Group type: EXPERIMENTAL
Intervention: rAMIRA imaging for ALS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Histopathologic analysis
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 38
Study: 39287521

Group type: EXPERIMENTAL
Intervention: BML progression
Number of subjects: 2430

Group type: COMPARATOR
Intervention: BML regression
Number of subjects: 2430

Group type: COMPARATOR
Intervention: BML-free
Number of subjects: 2430
Study: 39287522

Group type: EXPERIMENTAL
Intervention: AI-based segmentation for multiple structures, coronary artery calcium (CAC), and epicardial adipose tissue with automated feature extraction methods and machine learning.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ensemble AI models for predicting ACM and extrapulmonary significant incidental findings.
Number of subjects: 0
Study: 39287532

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg pro re nata
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Baseline subretinal fluid thickness
Number of subjects: 236
Study: 39287534

Group type: EXPERIMENTAL
Intervention: Home optical coherence tomography (OCT) management
Number of subjects: 15
Study: 39287566

Group type: EXPERIMENTAL
Intervention: First-line protease inhibitor (PI)-based regimen
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Younger caregivers
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: GBTM (Group-Based Trajectory Modeling)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Caregiver and regimen-related characteristics
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tailored counseling for younger caregivers
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Palatable regimens
Number of subjects: 89
Study: 39287606

Group type: EXPERIMENTAL
Intervention: Mathematical model predicting relapse probability based on M-protein dynamics and response histories up to 12 months of treatment.
Number of subjects: 470

Group type: COMPARATOR
Intervention: M-protein velocity assessment.
Number of subjects: 470
Study: 39287731

Group type: EXPERIMENTAL
Intervention: auto-VTI® tool
Number of subjects: 70

Group type: COMPARATOR
Intervention: manual measurements of VTI-LVOT
Number of subjects: 70
Study: 39287733

Group type: EXPERIMENTAL
Intervention: SCOPE-ATI study participants
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Role of study staff
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psychosocial risks of pausing ART
Number of subjects: 12
Study: 39287821

Group type: EXPERIMENTAL
Intervention: ABBV-011 monotherapy (1.0 mg/kg every 3 weeks)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ABBV-011 monotherapy (various doses up to 2.0 mg/kg)
Number of subjects: 99
Study: 39287964

Group type: EXPERIMENTAL
Intervention: Onradivir 600 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Onradivir 600 mg (mild hepatic impairment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Onradivir 600 mg (moderate hepatic impairment)
Number of subjects: 24
Study: 39287991

Group type: EXPERIMENTAL
Intervention: Vaccination against KRASMUT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-A*03:01 and HLA-A*11:01-restricted TCR-redirected CD8+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-A*11:01-restricted TCR-T CD4+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KRASG12V-specific TCRs
Number of subjects: 0
Study: 39288308

Group type: EXPERIMENTAL
Intervention: Mailed outreach for HCC screening
Number of subjects: 1436
Study: 39288343

Group type: EXPERIMENTAL
Intervention: TNR expansion (>40)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TNR expansion
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ETDRS score
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ETDRS score with glare
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Central corneal thickness and Visual Function and Corneal Health Status scores
Number of subjects: 104
Study: 39288368

Group type: EXPERIMENTAL
Intervention: Lung-Protective Mechanical Ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39288373

Group type: EXPERIMENTAL
Intervention: Peer Intervention to Link Overdose survivors to Treatment (PILOT) - a 6-month, PSS-led intervention tailored to each participant's goals to reduce overdose risk behavior.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) - standard-of-care overdose materials, education, and services provided through the participating EDs.
Number of subjects: 150
Study: 39288507

Group type: EXPERIMENTAL
Intervention: Multidisciplinary geriatric follow-up
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 363
Study: 39288528

Group type: EXPERIMENTAL
Intervention: PIPAC-OX (90 mg/m2) combined with systemic nivolumab
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PIPAC-OX and nivolumab
Number of subjects: 18
Study: 39288676

Group type: EXPERIMENTAL
Intervention: High nutritional status trajectory
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Low nutritional status trajectory
Number of subjects: 112

Group type: COMPARATOR
Intervention: Symptom severity
Number of subjects: 112

Group type: COMPARATOR
Intervention: Older age and surgical complications
Number of subjects: 112
Study: 39288779

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemoradiotherapy
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo-chemoradiotherapy
Number of subjects: 1060
Study: 39288781

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant pembrolizumab (200 mg IV every 3 weeks)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Neoadjuvant placebo (IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant placebo (IV every 3 weeks)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy
Number of subjects: 797

Group type: COMPARATOR
Intervention: Neoadjuvant placebo plus chemotherapy
Number of subjects: 797
Study: 39288844

Group type: EXPERIMENTAL
Intervention: Subcutaneous nivolumab (1200 mg every 4 weeks)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Intravenous nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 495